CNS Drugs

, Volume 24, Issue 2, pp 131–161 | Cite as

Therapeutic Options for Treatment-Resistant Depression

  • Richard C. Shelton
  • Olawale Osuntokun
  • Alexandra N. Heinloth
  • Sara A. Corya
Review Article

Abstract

Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health’s (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the failure of two treatment trials, the chances of remission decrease significantly.

Several pharmacological and nonpharmacological treatments for TRD may be considered when optimized (adequate dose and duration) therapy has not produced a successful outcome and a patient is classified as resistant to treatment. Nonpharmacological strategies include psychotherapy (often in conjunction with pharmacotherapy), electroconvulsive therapy and vagus nerve stimulation. The US FDA recently approved vagus nerve stimulation as adjunctive therapy (after four prior treatment failures); however, its benefits are seen only after prolonged (up to 1 year) use. Other nonpharmacological options, such as repetitive transcranial stimulation, deep brain stimulation or psychosurgery, remain experimental and are not widely available.

Pharmacological treatments of TRD can be grouped in two main categories: ‘switching’ or ‘combining’. In the first, treatment is switched within and between classes of compounds. The benefits of switching include avoidance of polypharmacy, a narrower range of treatment-emergent adverse events and lower costs. An inherent disadvantage of any switching strategy is that partial treatment responses resulting from the initial treatment might be lost by its discontinuation in favour of another medication trial. Monotherapy switches have also been shown to have limited effectiveness in achieving remission.

The advantage of combination strategies is the potential to build upon achieved improvements; they are generally recommended if partial response was achieved with the current treatment trial. Various non-antidepressant augmenting agents, such as lithium and thyroid hormones, are well studied, although not commonly used. There is also evidence of efficacy and increasing use of atypical antipsychotics in combination with antidepressants, for example, olanzapine in combination with fluoxetine (OFC) or augmentation with aripiprazole. The disadvantages of a combination strategy include multiple medications, a broader range of treatment-emergent adverse events and higher costs.

Several experimental pharmaceutical treatment alternatives for TRD are also being explored in combination with antidepressants or as monotherapy. These less studied alternative compounds include pindolol, inositol, CNS stimulants, hormones, herbal supplements, omega-3 fatty acids, S-adenosyl-L-methionine, folic acid, lamotrigine, modafinil, riluzole and topiramate.

In summary, despite an increasing variety of choices for the treatment of TRD, this condition remains universally undefined and represents an area of unmet medical need. There are few known approved pharmacological agents for TRD (aripiprazole and OFC) and overall outcomes remain poor. This might be an indication that depression itself is a heterogeneous condition with a great diversity of pathologies, highlighting the need for careful evaluation of individuals with depressive symptoms who are unresponsive to treatment. Clearly, more research is needed to provide clinicians with better guidance in making those treatment decisions — especially in light of accumulating evidence that the longer patients are unsuccessfully treated, the worse their long-term prognosis tends to be.

Notes

Acknowledgements

This work was sponsored by Eli Lilly and Company.

Dr Shelton has received grants/research support from Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals, Janssen Pharmaceutica, Pfizer Inc., Sanofi Pharmaceutica, Wyeth-Ayerst Laboratories, AstraZeneca Pharmaceutica and Abbott Laboratories; he was a paid consultant for Pfizer Inc. and Janssen Pharmaceutica; he has participated on speakers’ bureaus for Bristol-Myers Squibb, Eli Lilly and Company, Janssen Pharmaceutica, Pfizer Inc., GlaxoSmithKline Pharmaceuticals, Solvay Pharmaceuticals Inc., Wyeth-Ayerst Laboratories and Abbott Laboratories. Drs Osuntokun and Corya are full-time employees of Eli Lilly and Company. Dr Heinloth is a scientific writer employed full time by i3Statprobe, a division of Ingenix, which is a subsidiary of UnitedHealth Group; Eli Lilly contracted the technical writing of this manuscript with i3 Statprobe. Eli Lilly was involved in collection and interpretation of the presented data, and reviewed and approved the manuscript.

The authors thank Caron Modeas, i3Statprobe, for assistance in reviewing and editing the manuscript.

References

  1. 1.
    Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 Jan; 51(1): 8–19PubMedCrossRefGoogle Scholar
  2. 2.
    Waraich P, Goldner EM, Somers JM, et al. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 2004 Feb; 49(2): 124–38PubMedGoogle Scholar
  3. 3.
    Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006 Jan; 163(1): 28–40PubMedCrossRefGoogle Scholar
  4. 4.
    Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006 Mar; 354(12): 1231–42PubMedCrossRefGoogle Scholar
  5. 5.
    Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin NorthAm 1996 Jun; 19(2): 371–86CrossRefGoogle Scholar
  6. 6.
    Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996 Jun; 19(2): 179–200PubMedCrossRefGoogle Scholar
  7. 7.
    Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990 Jun; 51 Suppl.: 39–47PubMedGoogle Scholar
  8. 8.
    Nelson JC. The STAR*D study: a four-course meal that leaves us wanting more. Am J Psychiatry 2006 Nov; 163(11): 1864–6PubMedCrossRefGoogle Scholar
  9. 9.
    Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006 Nov; 163(11): 1905–17PubMedCrossRefGoogle Scholar
  10. 10.
    Sussman N. Translating science into service: Lessons Learned From the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Prim Care Companion J Clin Psychiatry 2007; 9(5): 331–7PubMedCrossRefGoogle Scholar
  11. 11.
    Fava GA, Tomba E, Grandi S. The road to recovery from depression: don’t drive today with yesterday’s map. Psychother Psychosom 2007; 76(5): 260–5PubMedCrossRefGoogle Scholar
  12. 12.
    Keitner GI, Solomon DA, Ryan CE. STAR*D: have we learned the right lessons? Am J Psychiatry 2008 Jan; 165(1): 133–4PubMedCrossRefGoogle Scholar
  13. 13.
    Corey-Lisle PK, Birnbaum HG, Greenberg PE, et al. Identification of a claims data “signature” and economic consequences for treatment-resistant depression. J Clin Psychiatry 2002 Aug; 63(8): 717–26PubMedCrossRefGoogle Scholar
  14. 14.
    Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004 Mar; 65(3): 341–7PubMedCrossRefGoogle Scholar
  15. 15.
    Papakostas GI, Petersen T, Pava J, et al. Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. J Nerv Ment Dis 2003 Jul; 191(7): 444–9PubMedCrossRefGoogle Scholar
  16. 16.
    Hamilton M. A rating scale for depression. J Neurol Neuro-surg Psychiatry 1960 Feb; 23: 56–62CrossRefGoogle Scholar
  17. 17.
    Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001; 62 Suppl. 16: 26–31Google Scholar
  18. 18.
    Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001; 62 Suppl. 16: 10–7Google Scholar
  19. 19.
    Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58 Suppl. 13: 23–9Google Scholar
  20. 20.
    Hetrick SE, Parker AG, Hickie IB, et al. Early identification and intervention in depressive disorders: towards a clinical staging model. Psychother Psychosom 2008; 77(5): 263–70PubMedCrossRefGoogle Scholar
  21. 21.
    Thase ME. Therapeutic alternatives for difficult-to-treatdepression: a narrative review of the state of the evidence.CNS Spectr 2004 Nov; 9(11): 808–21Google Scholar
  22. 22.
    Abbass AA. Intensive short-term dynamic psychotherapy of treatment-resistant depression: a pilot study. Depress Anxiety 2006; 23(7): 449–52PubMedCrossRefGoogle Scholar
  23. 23.
    Thase ME, Howland RH. Refractory depression: relevance of psychosocial factors and therapies. Psychiatr Ann 1994; 24: 232–40Google Scholar
  24. 24.
    Fava GA, Savron G, Grandi S, et al. Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry 1997 Jun; 58(6): 278–82PubMedCrossRefGoogle Scholar
  25. 25.
    McPherson S, Cairns P, Carlyle J, et al. The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand 2005 May; 111(5): 331–40PubMedCrossRefGoogle Scholar
  26. 26.
    Michalak EE, Lam RW. Breaking the myths: new treatment approaches for chronic depression. Can J Psychiatry 2002 Sep; 47(7): 635–43PubMedGoogle Scholar
  27. 27.
    Bannan N. Multimodal therapy of treatment resistant depression: a study and analysis. Int J Psychiatry Med 2005; 35(1): 27–39PubMedCrossRefGoogle Scholar
  28. 28.
    Teasdale JD, Scott J, Moore RG, et al. How does cognitive therapy prevent relapse in residual depression? Evidence from a controlled trial. J Consult Clin Psychol 2001 Jun; 69(3): 347–57PubMedCrossRefGoogle Scholar
  29. 29.
    Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000 May; 342(20): 1462–70PubMedCrossRefGoogle Scholar
  30. 30.
    Schatzberg AF, Rush AJ, Arnow BA, et al. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry 2005 May; 62(5): 513–20PubMedCrossRefGoogle Scholar
  31. 31.
    Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 1999 Sep; 56(9): 829–35PubMedCrossRefGoogle Scholar
  32. 32.
    Depression Guideline Panel. Clinical practice guideline number 5: depression in primary care. Vol 2. Treatment of major depression. Rockville (MD): US Dept of Health and Human Services, Agency for Health Care Policy and Research, 1993Google Scholar
  33. 33.
    Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007 May; 164(5): 739–52PubMedCrossRefGoogle Scholar
  34. 34.
    Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. AMA 2008 Feb; 299(8): 901–13CrossRefGoogle Scholar
  35. 35.
    Fink M. Convulsive therapy: a review of the first 55 years. J Affect Disord 2001 Mar; 63(1–3): 1–15PubMedCrossRefGoogle Scholar
  36. 36.
    Ishihara K, Sasa M. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol 1999 Jul; 80(3): 185–9PubMedCrossRefGoogle Scholar
  37. 37.
    Takano H, Motohashi N, Uema T, et al. Changes in regional cerebral blood flow during acute electroconvulsive therapy in patients with depression: positron emission tomographic study. Br J Psychiatry 2007 Jan; 190: 63–8PubMedCrossRefGoogle Scholar
  38. 38.
    Segawa K, Azuma H, Sato K, et al. Regional cerebral blood flow changes in depression after electroconvulsive therapy. Psychiatry Res 2006 Oct; 147(2-3): 135–43PubMedCrossRefGoogle Scholar
  39. 39.
    Vangu MD, Esser JD, Boyd IH, et al. Effects of electroconvulsive therapy on regional cerebral blood flow measured by 99mtechnetium HMPAO SPECT. Prog Neuropsycho-pharmacol Biol Psychiatry 2003 Feb; 27(1): 15–9CrossRefGoogle Scholar
  40. 40.
    Muller U, Klimke A, Janner M, et al. Electroconvulsive therapy in psychiatric clinics in Germany in 1995. Nervenarzt 1998 Jan; 69(1): 15–26PubMedCrossRefGoogle Scholar
  41. 41.
    Husain SS, Kevan IM, Linnell R, et al. What do psychiatrists mean by medication resistance as an indication for electroconvulsive therapy? J ECT 2005 Dec; 21(4): 211–3PubMedCrossRefGoogle Scholar
  42. 42.
    Eschweiler GW, Vontheim R, Bode R, et al. Clinical efficacy and cognitive side effects of bifrontal versus right unilateral electroconvulsive therapy (ECT): a short-term randomized controlled trial in pharmaco-resistant major depression. J Affect Disord 2007 Aug; 101(1–3): 149–57PubMedCrossRefGoogle Scholar
  43. 43.
    Frey R, Schreinzer D, Heiden A, et al. Use of electroconvulsive therapy in psychiatry. Nervenarzt 2001 Sep; 72(9): 661–76PubMedCrossRefGoogle Scholar
  44. 44.
    Wijkstra J, Nolen WA, Algra A, et al. Relapse prevention in major depressive disorder after successful ECT: a literature review and a naturalistic case series. Acta Psychiatr Scand 2000 Dec; 102(6): 454–60PubMedCrossRefGoogle Scholar
  45. 45.
    Pagnin D, de Queiroz V, Pini S, et al. Efficacy of ECT in depression: a meta-analytic review. J ECT 2004 Mar; 20(1): 13–20PubMedCrossRefGoogle Scholar
  46. 46.
    Dannon PN, Grunhaus L. Effect of electroconvulsive therapy in repetitive transcranial magnetic stimulation non-responder MDD patients: a preliminary study. Int J Neuropsychopharmacol 2001 Sep; 4(3): 265–8PubMedCrossRefGoogle Scholar
  47. 47.
    Folkerts HW, Michael N, Tolle R, et al. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression: a randomized study. Acta Psychiatr Scand 1997 Nov; 96(5): 334–42Google Scholar
  48. 48.
    Kornhuber J, Weller M. Patient selection and remission rates with the current practice of electroconvulsive therapy in Germany. Convuls Ther 1995 Jun; 11(2): 104–9PubMedGoogle Scholar
  49. 49.
    Patel M, Patel S, Hardy DW, et al. Should electroconvulsive therapy be an early consideration for suicidal patients? J ECT 2006 Jun; 22(2): 113–5PubMedCrossRefGoogle Scholar
  50. 50.
    Bradvik L, Berglund M. Long-term treatment and suicidal behavior in severe depression: ECT and antidepressant pharmacotherapy may have different effects on the occurrence and seriousness of suicide attempts. Depress Anxiety 2006; 23(1): 34–41PubMedCrossRefGoogle Scholar
  51. 51.
    Kellner CH, Fink M, Knapp R, et al. Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Am J Psychiatry 2005 May; 162(5): 977–82PubMedCrossRefGoogle Scholar
  52. 52.
    Devanand DP, Sackeim HA, Prudic J. Electroconvulsive therapy in the treatment-resistant patient. Psychiatr Clin North Am 1991 Dec; 14(4): 905–23PubMedGoogle Scholar
  53. 53.
    Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001 Mar; 285(10): 1299–307PubMedCrossRefGoogle Scholar
  54. 54.
    McCall WV. Electroconvulsive therapy in the era of modern psychopharmacology. Int J Neuropsychopharmacol 2001 Sep; 4(3): 315–24PubMedCrossRefGoogle Scholar
  55. 55.
    Ingram A, Saling MM, Schweitzer I. Cognitive side effects of brief pulse electroconvulsive therapy: a review. J ECT 2008 Mar; 24(1): 3–9PubMedCrossRefGoogle Scholar
  56. 56.
    Squire LR, Chace PM. Memory functions six to nine months after electroconvulsive therapy. Arch Gen Psychiatry 1975 Dec; 32(12): 1557–64PubMedCrossRefGoogle Scholar
  57. 57.
    Strain JJ, Brunschwig L, Duffy JP, et al. Comparison of therapeutic effects and memory changes with bilateral and unilateral ECT. Am J Psychiatry 1968 Sep; 125(3): 50–60PubMedGoogle Scholar
  58. 58.
    Williams M. Memory studies in electric convulsion therapy. J Neurol Neurosurg Psychiatry 1950 Feb; 13(1): 30–5PubMedCrossRefGoogle Scholar
  59. 59.
    Donahue AB. Electroconvulsive therapy and memory loss: a personal journey. J ECT 2000 Jun; 16(2): 133–43PubMedCrossRefGoogle Scholar
  60. 60.
    Hihn H, Baune BT, Michael N, et al. Memory performance in severely depressed patients treated by electroconvulsive therapy. J ECT 2006 Sep; 22(3): 189–95PubMedCrossRefGoogle Scholar
  61. 61.
    Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 1993 Mar; 328(12): 839–46PubMedCrossRefGoogle Scholar
  62. 62.
    Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 2000 May; 57(5): 425–34PubMedCrossRefGoogle Scholar
  63. 63.
    Lawson JS, Inglis J, Delva NJ, et al. Electrode placement in ECT: cognitive effects. Psychol Med 1990 May; 20(2): 335–44PubMedCrossRefGoogle Scholar
  64. 64.
    McCall WV, Reboussin DM, Weiner RD, et al. Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry 2000 May; 57(5): 438–44PubMedCrossRefGoogle Scholar
  65. 65.
    Sackeim HA, Prudic J, Fuller R, et al. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology 2007 Jan; 32(1): 244–54PubMedCrossRefGoogle Scholar
  66. 66.
    Shapira B, Tubi N, Drexler H, et al. Cost and benefit in the choice of ECT schedule: twice versus three times weekly ECT. Br J Psychiatry 1998 Jan; 172: 44–8PubMedCrossRefGoogle Scholar
  67. 67.
    Shapira B, Tubi N, Lerer B. Balancing speed of response to ECT in major depression and adverse cognitive effects: role of treatment schedule. J ECT 2000 Jun; 16(2): 97–109PubMedCrossRefGoogle Scholar
  68. 68.
    Ingram A, Schweitzer I, Ng CH, et al. A comparison of propofol and thiopentone use in electroconvulsive therapy: cognitive and efficacy effects. J ECT 2007 Sep; 23(3): 158–62PubMedCrossRefGoogle Scholar
  69. 69.
    Legendre SA, Stern RA, Solomon DA, et al. The influence of cognitive reserve on memory following electroconvulsive therapy. J Neuropsychiatry Clin Neurosci 2003; 15(3): 333–9PubMedCrossRefGoogle Scholar
  70. 70.
    Rao V, Lyketsos CG. The benefits and risks of ECT for patients with primary dementia who also suffer from depression. Int J Geriatr Psychiatry 2000 Aug; 15(8): 729–35PubMedCrossRefGoogle Scholar
  71. 71.
    Steif BL, Sackeim HA, Portnoy S, et al. Effects of depression and ECT on anterograde memory. Biol Psychiatry 1986 Aug; 21(10): 921–30PubMedCrossRefGoogle Scholar
  72. 72.
    Zervas IM, Calev A, Jandorf L, et al. Age-dependent effects of electroconvulsive therapy on memory. Convuls Ther 1993; 9(1): 39–42PubMedGoogle Scholar
  73. 73.
    Weiner SJ, Ward TN, Ravaris CL. Headache and electroconvulsive therapy. Headache 1994 Mar; 34(3): 155–9PubMedCrossRefGoogle Scholar
  74. 74.
    Datto CJ. Side effects of electroconvulsive therapy. Depress Anxiety 2000; 12(3): 130–4PubMedCrossRefGoogle Scholar
  75. 75.
    Kramer BA, Kadar AG, Clark K. Transcutaneous acupoint electrical stimulation in preventing and treating nausea and vomiting in patients receiving electroconvulsive therapy. J ECT 2003 Dec; 19(4): 194–6PubMedCrossRefGoogle Scholar
  76. 76.
    Lee K. Acute embolic stroke after electroconvulsive therapy. J ECT 2006 Mar; 22(1): 67–9PubMedCrossRefGoogle Scholar
  77. 77.
    Loo CK, MacPherson R, Woodey R, et al. Supraorbital edema induced by electroconvulsive therapy. J ECT 2005 Dec; 21(4): 249–50PubMedCrossRefGoogle Scholar
  78. 78.
    Andrade C, Gangadhar BN, Swaminath G, et al. Mania as a side effect of electroconvulsive therapy. Convuls Ther 1988; 4(1): 81–3PubMedGoogle Scholar
  79. 79.
    Nemeroff CB, Mayberg HS, Krahl SE, et al. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 2006 Jul; 31(7): 1345–55PubMedCrossRefGoogle Scholar
  80. 80.
    Hoppe C, Helmstaedter C, Scherrmann J, et al. Self-reported mood changes following 6 months of vagus nerve stimulation in epilepsy patients. Epilepsy Behav 2001 Aug; 2(4): 335–42PubMedCrossRefGoogle Scholar
  81. 81.
    Elger G, Hoppe C, Falkai P, et al. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res 2000 Dec; 42(2–3): 203–10PubMedCrossRefGoogle Scholar
  82. 82.
    Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 2000 Feb; 47(4): 276–86PubMedCrossRefGoogle Scholar
  83. 83.
    Corcoran CD, Thomas P, Phillips J, et al. Vagus nerve stimulation in chronic treatment-resistant depression: preliminary findings of an open-label study. Br J Psychiatry 2006 Sep; 189: 282–3PubMedCrossRefGoogle Scholar
  84. 84.
    Patwardhan R, Cardenas R, Myers D, et al. Left vagus nerve stimulation for depression: first implantation case post-FDA approval and review of the literature. J La State Med Soc 2007 Jan; 159(1): 38–41PubMedGoogle Scholar
  85. 85.
    Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001 Nov; 25(5): 713–28PubMedCrossRefGoogle Scholar
  86. 86.
    Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005 Sep; 58(5): 347–54PubMedCrossRefGoogle Scholar
  87. 87.
    Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005 Sep; 66(9): 1097–104PubMedCrossRefGoogle Scholar
  88. 88.
    George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005 Sep; 58(5): 364–73PubMedCrossRefGoogle Scholar
  89. 89.
    Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005 Sep; 58(5): 355–63PubMedCrossRefGoogle Scholar
  90. 90.
    George MS, Nahas Z, Borckardt JJ, et al. Vagus nerve stimulation for the treatment of depression and other neuropsychiatric disorders. Expert Rev Neurother 2007 Jan; 7(1): 63–74PubMedCrossRefGoogle Scholar
  91. 91.
    Conway CR, Sheline YI, Chibnall JT, et al. Cerebral blood flow changes during vagus nerve stimulation for depression. Psychiatry Res 2006 Mar; 146(2): 179–84PubMedCrossRefGoogle Scholar
  92. 92.
    Dorr AE, Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. J Pharmacol Exp Ther 2006 Aug; 318(2): 890–8PubMedCrossRefGoogle Scholar
  93. 93.
    Nahas Z, Teneback C, Chae JH, et al. Serial vagus nerve stimulation functional MRI in treatment-resistant depression. Neuropsychopharmacology 2007 Aug; 32(8): 1649–60PubMedCrossRefGoogle Scholar
  94. 94.
    Bajbouj M, Gallinat J, Lang UE, et al. Motor cortex excitability after vagus nerve stimulation in major depression. J Clin Psychopharmacol 2007 Apr; 27(2): 156–9PubMedCrossRefGoogle Scholar
  95. 95.
    Critchley HD, Lewis PA, Orth M, et al. Vagus nerve stimulation for treatment-resistant depression: behavioral and neural effects on encoding negative material. Psychosom Med 2007 Jan; 69(1): 17–22PubMedCrossRefGoogle Scholar
  96. 96.
    Carpenter LL, Moreno FA, Kling MA, et al. Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. Biol Psychiatry 2004 Sep; 56(6): 418–26PubMedCrossRefGoogle Scholar
  97. 97.
    Corcoran C, Connor TJ, O’Keane V, et al. The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in humans: a preliminary report. Neuroimmuno-modulation 2005; 12(5): 307–9CrossRefGoogle Scholar
  98. 98.
    Lang UE, Bajbouj M, Gallinat J, et al. Brain-derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation. Psychopharmacology (Berl) 2006 Jul; 187(1): 56–9CrossRefGoogle Scholar
  99. 99.
    Shafique S, Dalsing MC. Vagus nerve stimulation therapy for treatment of drug-resistant epilepsy and depression. Perspect Vasc Surg Endovasc Ther 2006 Dec; 18(4): 323–7PubMedCrossRefGoogle Scholar
  100. 100.
    Sackeim HA, Keilp JG, Rush AJ, et al. The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression. Neuropsychiatry Neuropsychol Behav Neurol 2001 Jan; 14(1): 53–62PubMedGoogle Scholar
  101. 101.
    Borckardt JJ, Anderson B, Andrew KF, et al. Acute and long-term VNS effects on pain perception in a case of treatment-resistant depression. Neurocase 2006 Aug; 12(4): 216–20PubMedCrossRefGoogle Scholar
  102. 102.
    Bodenlos JS, Kose S, Borckardt JJ, et al. Vagus nerve stimulation acutely alters food craving in adults with depression. Appetite 2007 Mar; 48(2): 145–53PubMedCrossRefGoogle Scholar
  103. 103.
    Bickford RG, Guidi M, Fortesque P, et al. Magnetic stimulation of human peripheral nerve and brain: response enhancement by combined magnetoelectrical technique. Neurosurgery 1987 Jan; 20(1): 110–6PubMedCrossRefGoogle Scholar
  104. 104.
    George MS, Wassermann EM, Williams WA, et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport 1995 Oct; 6(14): 1853–6PubMedCrossRefGoogle Scholar
  105. 105.
    Pascual-Leone A, Rubio B, Pallardo F, et al. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 1996 Jul; 348(9022): 233–7PubMedCrossRefGoogle Scholar
  106. 106.
    Triggs WJ, McCoy KJ, Greer R, et al. Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold. Biol Psychiatry 1999 Jun;45(11): 1440–6PubMedCrossRefGoogle Scholar
  107. 107.
    Grunhaus L, Schreiber S, Dolberg OT, et al. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry 2003 Feb; 53(4): 324–31PubMedCrossRefGoogle Scholar
  108. 108.
    Avery DH, Holtzheimer III PE, Fawaz W, et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006 Jan; 59(2): 187–94PubMedCrossRefGoogle Scholar
  109. 109.
    Rossini D, Lucca A, Zanardi R, et al. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res 2005 Nov; 137(1–2): 1–10PubMedCrossRefGoogle Scholar
  110. 110.
    Rossini D, Magri L, Lucca A, et al. Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial. J Clin Psychiatry 2005 Dec; 66(12): 1569–75PubMedCrossRefGoogle Scholar
  111. 111.
    Isenberg K, Downs D, Pierce K, et al. Low frequency rTMS stimulation of the right frontal cortex is as effective as high frequency rTMS stimulation of the left frontal cortex for antidepressant-free, treatment-resistant depressed patients. Ann Clin Psychiatry 2005 Jul; 17(3): 153–9PubMedCrossRefGoogle Scholar
  112. 112.
    Garcia-Toro M, Salva J, Daumal J, et al. High (20-Hz) and low (1-Hz) frequency transcranial magnetic stimulation as adjuvant treatment in medication-resistant depression. Psychiatry Res 2006 Jan; 146(1): 53–7PubMedCrossRefGoogle Scholar
  113. 113.
    Turnier-Shea Y, Bruno R, Pridmore S. Daily and spaced treatment with transcranial magnetic stimulation in major depression: a pilot study. Aust N Z J Psychiatry 2006 Sep; 40(9): 759–63PubMedCrossRefGoogle Scholar
  114. 114.
    Fitzgerald PB, Huntsman S, Gunewardene R, et al. A randomized trial of low-frequency right-prefrontal-cortex transcranial magnetic stimulation as augmentation in treatment-resistant major depression. Int J Neuropsycho-pharmacol 2006 Dec; 9(6): 655–66CrossRefGoogle Scholar
  115. 115.
    Loo CK, Mitchell PB, McFarquhar TF, et al. A sham-controlled trial of the efficacy and safety of twice-daily rTMS in major depression. Psychol Med 2007 Mar; 37(3): 341–9PubMedCrossRefGoogle Scholar
  116. 116.
    Padberg F, Zwanzger P, Thoma H, et al. Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Res 1999 Nov; 88(3): 163–71PubMedCrossRefGoogle Scholar
  117. 117.
    Loo C, Mitchell P, Sachdev P, et al. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am J Psychiatry 1999 Jun; 156(6): 946–8PubMedGoogle Scholar
  118. 118.
    Boutros NN, Gueorguieva R, Hoffman RE, et al. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. Psychiatry Res 2002 Dec; 113(3): 245–54PubMedCrossRefGoogle Scholar
  119. 119.
    Loo CK, Mitchell PB, Croker VM, et al. Double-blind controlled investigation of bilateral prefrontal transcranial magnetic stimulation for the treatment of resistant major depression. Psychol Med 2003 Jan; 33(1): 33–40PubMedCrossRefGoogle Scholar
  120. 120.
    Poulet E, Brunelin J, Boeuve C, et al. Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. Eur Psychiatry 2004 Sep; 19(6): 382–3PubMedCrossRefGoogle Scholar
  121. 121.
    Padberg F, Zwanzger P, Keck ME, et al. Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. Neuro-psychopharmacology 2002 Oct; 27(4): 638–45Google Scholar
  122. 122.
    Fitzgerald PB, Hoy K, Daskalakis ZJ, et al. A randomized trial of the anti-depressant effects of low- and high-frequency transcranial magnetic stimulation in treatment-resistant depression. Depress Anxiety 2009; 26(3); 229–34PubMedCrossRefGoogle Scholar
  123. 123.
    Miniussi C, Bonato C, Bignotti S, et al. Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression? Clin Neurophysiol 2005 May; 116(5): 1062–71PubMedCrossRefGoogle Scholar
  124. 124.
    Fitzgerald PB, Benitez J, de Castella A, et al. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am J Psychiatry 2006 Jan; 163(1): 88–94PubMedCrossRefGoogle Scholar
  125. 125.
    Fitzgerald PB, Brown TL, Marston NA, et al. Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 2003 Oct; 60(10): 1002–8PubMedGoogle Scholar
  126. 126.
    Su TP, Huang CC, Wei IH. Add-on rTMS for medication-resistant depression: a randomized, double-blind, sham-controlled trial in Chinese patients. J Clin Psychiatry 2005 Jul; 66(7): 930–7PubMedCrossRefGoogle Scholar
  127. 127.
    Huang CC, Su TP, Wei IH. Repetitive transcranial magnetic stimulation for treating medication-resistant depression in Taiwan: a preliminary study. J Chin Med Assoc 2005 May; 68(5): 210–5PubMedCrossRefGoogle Scholar
  128. 128.
    Huang CC, Su TP, Shan IK, et al. An open trial of daily left prefrontal cortex repetitive transcranial magnetic stimulation for treating medication-resistant depression. Eur Psychiatry 2004 Dec; 19(8): 523–4PubMedCrossRefGoogle Scholar
  129. 129.
    Fregni F, Marcolin MA, Myczkowski M, et al. Predictors of antidepressant response in clinical trials of transcranial magnetic stimulation. Int J Neuropsychopharmacol 2006 Dec; 9(6): 641–54PubMedCrossRefGoogle Scholar
  130. 130.
    Fabre I, Galinowski A, Oppenheim C, et al. Antidepressant efficacy and cognitive effects of repetitive transcranial magnetic stimulation in vascular depression: an open trial. Int J Geriatr Psychiatry 2004 Sep; 19(9): 833–42PubMedCrossRefGoogle Scholar
  131. 131.
    Mosimann UP, Schmitt W, Greenberg BD, et al. Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. Psychiatry Res 2004 Apr; 126(2): 123–33PubMedCrossRefGoogle Scholar
  132. 132.
    Nahas Z, Li X, Kozel FA, et al. Safety and benefits of dist nce-adjusted prefrontal transcranial magnetic stimulation in depressed patients 55–75 years of age: a pilot study. Depress Anxiety 2004; 19(4): 249–56PubMedCrossRefGoogle Scholar
  133. 133.
    Fitzgerald PB, Hoy K, McQueen S, et al. A randomized trial of rTMS targeted with MRI based neuro-navigation in treatment-resistant depression. Neuropsychopharmacology 2009 Apr; 34(5): 1255–62PubMedCrossRefGoogle Scholar
  134. 134.
    Sakkas P, Mihalopoulou P, Mourtzouhou P, et al. Induction of mania by rTMS: report of two cases. Eur Psychiatry 2003 Jun; 18(4): 196–8PubMedCrossRefGoogle Scholar
  135. 135.
    Conca A, Konig P, Hausmann A. Transcranial magnetic stimulation induces ‘pseudoabsence seizure’. Acta Psychiatr Scand 2000 Mar; 101(3): 246–8PubMedCrossRefGoogle Scholar
  136. 136.
    Martis B, Alam D, Dowd SM, et al. Neurocognitive effects of repetitive transcranial magnetic stimulation in severe major depression. Clin Neurophysiol 2003 Jun; 114(6): 1125–32PubMedCrossRefGoogle Scholar
  137. 137.
    Conca A, Peschina W, Konig P, et al. Effect of chronic repetitive transcranial magnetic stimulation on regional cerebral blood flow and regional cerebral glucose uptake in drug treatment-resistant depressives: a brief report. Neuropsychobiology 2002; 45(1): 27–31PubMedCrossRefGoogle Scholar
  138. 138.
    Nadeau SE, McCoy KJ, Crucian GP, et al. Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation: evidence of individual variability. Neuropsychiatry Neuropsychol Behav Neurol 2002 Sep; 15(3): 159–75PubMedGoogle Scholar
  139. 139.
    O’Reardon JP, Cristancho P, Pilania P, et al. Patients with a major depressive episode responding to treatment with repetitive transcranial magnetic stimulation (rTMS) are resistant to the effects of rapid tryptophan depletion. Depress Anxiety 2006; 24(8): 537–44CrossRefGoogle Scholar
  140. 140.
    Zanardini R, Gazzoli A, Ventriglia M, et al. Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J Affect Disord 2006 Mar; 91(1): 83–6PubMedCrossRefGoogle Scholar
  141. 141.
    Sachdev PS, Sachdev J. Long-term outcome of neuro-surgery for the treatment of resistant depression. J Neuropsychiatry Clin Neurosci 2005; 17(4): 478–85PubMedCrossRefGoogle Scholar
  142. 142.
    Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005 Mar; 45(5): 651–60PubMedCrossRefGoogle Scholar
  143. 143.
    Bewernick BH, Hurlemann R, Matusch A, et al. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry. Epub 2009 Nov 17Google Scholar
  144. 144.
    Jimenez F, Velasco F, Salin-Pascual R, et al. A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. Neuro- surgery 2005 Sep; 57(3): 585–93Google Scholar
  145. 145.
    Fava M. Diagnosis and definition of treatment-resistantdepression. Biol Psychiatry 2003 Apr; 53(8): 649–59PubMedCrossRefGoogle Scholar
  146. 146.
    Rao ML, Deister A, Laux G, et al. Low serum levels of tri-cyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse. Pharmacopsychiatry 1996 May; 29(3): 97–102PubMedCrossRefGoogle Scholar
  147. 147.
    Vormfelde SV, Bitsch A, Meineke I, et al. Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? Eur J Clin Pharmacol 1997; 52(5): 387–90PubMedCrossRefGoogle Scholar
  148. 148.
    Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders: IV. Medications and other biological treatments. Can J Psychiatry 2001 Jun; 46 Suppl. 1: 38S–58SGoogle Scholar
  149. 149.
    Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psycho-pharmacology guidelines: British Association for Psycho-pharmacology. J Psychopharmacol 2000 Mar; 14(1): 3–20PubMedCrossRefGoogle Scholar
  150. 150.
    Mulrow CD, Williams Jr JW, Trivedi M, et al. Treatment of depression: newer pharmacotherapies. Psychopharmacol Bull 1998; 34(4): 409–795PubMedGoogle Scholar
  151. 151.
    Rush AJ, Crismon ML, Toprac MG, et al. Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry 1998; 59 Suppl. 20: 73–84Google Scholar
  152. 152.
    Ruhe HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006 Dec; 67(12): 1836–55PubMedCrossRefGoogle Scholar
  153. 153.
    Joffe RT, Levitt AJ, Sokolov ST, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996 Mar; 57(3): 114–5PubMedGoogle Scholar
  154. 154.
    Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997 Jan; 58(1): 16–21PubMedCrossRefGoogle Scholar
  155. 155.
    Thase ME, Feighner JP, Lydiard RB. Citalopram treatment of fluoxetine nonresponders. J Clin Psychiatry 2001 Sep; 62(9): 683–7PubMedCrossRefGoogle Scholar
  156. 156.
    Zarate CA, Kando JC, Tohen M, et al. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996 Feb; 57(2): 67–71PubMedGoogle Scholar
  157. 157.
    Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995 Jan; 56(1): 30–4PubMedGoogle Scholar
  158. 158.
    Thase ME, Ferguson JM, Lydiard RB, et al. Citalopram treatment of paroxetine-intolerant depressed patients. Depress Anxiety 2002; 16(3): 128–33PubMedCrossRefGoogle Scholar
  159. 159.
    Calabrese JR, Londborg PD, Shelton MD, et al. Citalo-pram treatment of fluoxetine-intolerant depressed patients. J Clin Psychiatry 2003 May; 64(5): 562–7PubMedCrossRefGoogle Scholar
  160. 160.
    Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous anti-depressant failure: ARGOS study. Depress Anxiety 2005; 22(2): 68–76PubMedCrossRefGoogle Scholar
  161. 161.
    Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999 Jul; 175: 12–6PubMedCrossRefGoogle Scholar
  162. 162.
    Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006 Jul; 163(7): 1161–72PubMedCrossRefGoogle Scholar
  163. 163.
    Nierenberg AA, Papakostas GI, Petersen T, et al. Nortriptyline for treatment-resistant depression. J Clin Psychiatry 2003 Jan; 64(1): 35–9PubMedCrossRefGoogle Scholar
  164. 164.
    Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression: I. Non-tricyclic and selective re-uptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988 Dec; 78(6): 668–75Google Scholar
  165. 165.
    Peselow ED, Filippi AM, Goodnick P, et al. The short- and long-term efficacy of paroxetine HCl: B. Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo. Psychopharmacol Bull 1989; 25(2): 272–6Google Scholar
  166. 166.
    Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of anti-depressant-resistant chronic depression. Arch Gen Psychiatry 2002 Mar; 59(3): 233–9PubMedCrossRefGoogle Scholar
  167. 167.
    Ferreri M, Lavergne F, Berlin I, et al. Benefits from mian-serin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 2001 Jan; 103(1): 66–72PubMedCrossRefGoogle Scholar
  168. 168.
    Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001 Jun; 62(6): 413–20PubMedCrossRefGoogle Scholar
  169. 169.
    Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther 2002 Jul; 24(7): 1194–200PubMedCrossRefGoogle Scholar
  170. 170.
    Mischoulon D, Opitz G, Kelly K, et al. A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment. Depress Anxiety 2004; 19(1): 43–50PubMedCrossRefGoogle Scholar
  171. 171.
    Mitchell PB, Schweitzer I, Burrows G, et al. Efficacy of venlafaxine and predictors of response in a prospective pen-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol 2000 Aug; 20(4): 483–7PubMedCrossRefGoogle Scholar
  172. 172.
    De Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999 Oct; 19(5): 401–6PubMedCrossRefGoogle Scholar
  173. 173.
    Poirier MF. The concept of resistant depression and therapeutic strategies, particularly, with venlafaxine. Encephale 1999 Jun; 25 Spec No. 2: 55–7Google Scholar
  174. 174.
    Reynaert-Dupuis C, Zdanowicza N, Leyman S, et al. Efficacy and tolerance of venlafaxinbe in depressed patients switched from prior antidepressant treatment. Primary Care Psychiatry 2002 Jun; 8(2): 63–8CrossRefGoogle Scholar
  175. 175.
    Saiz-Ruiz J, Ibanez A, az-Marsa M, et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol iol Psychiatry 2002 Oct; 26(6): 1129–34CrossRefGoogle Scholar
  176. 176.
    Wan DD, Kundhur D, Solomons K, et al. Mirtazapine for treatment-resistant depression: a preliminary report. J Psychiatry Neurosci 2003 Jan; 28(1): 55–9PubMedGoogle Scholar
  177. 177.
    Fava M, Papakostas GI, Petersen T, et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry 2003 Mar; 15(1): 17–22PubMedGoogle Scholar
  178. 178.
    Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched o bupropion. J Clin Psychiatry 1993 Dec; 54(12): 459–65PubMedGoogle Scholar
  179. 179.
    Fava M, McGrath PJ, Sheu WP. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol 2003 Aug; 23(4): 365–9PubMedCrossRefGoogle Scholar
  180. 180.
    Segui J, López-Munoz F, Alamo C, et al. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study. J Psychopharmacol. Epub 2009 Mar 12Google Scholar
  181. 181.
    McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006 Sep; 163(9): 1531–41PubMedCrossRefGoogle Scholar
  182. 182.
    Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression: II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988 Dec; 78(6): 676–83Google Scholar
  183. 183.
    Nolen WA, van de Putte JJ, Dijken WA, et al. L-5HTP indepression resistant to re-uptake inhibitors. An open comparative study with tranylcypromine. Br J Psychiatry 1985 Jul; 147: 16–22Google Scholar
  184. 184.
    Levitt AJ, Russell TJ, Kamil R, et al. Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination? J Clin Psychiatry 1999; 60(9): 613–6PubMedCrossRefGoogle Scholar
  185. 185.
    Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts non-responders to responders: a preliminary report. J Clin Psychiatry 1989 Dec; 50(12): 447–9PubMedGoogle Scholar
  186. 186.
    Fava M, Alpert JE, Nierenberg AA, et al. Double-blind study of high-dose fluoxetine versus lithium or desipra-mine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002; 22(4): 379–87PubMedCrossRefGoogle Scholar
  187. 187.
    Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994 Sep; 151(9): 1372–4PubMedGoogle Scholar
  188. 188.
    Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 2002 May; 161(2): 143–51CrossRefGoogle Scholar
  189. 189.
    Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic anti-depressant interaction. Clin Pharmacol Ther 1992 Mar; 51(3): 239–48PubMedCrossRefGoogle Scholar
  190. 190.
    Nelson JC, Mazure CM, Bowers Jr MB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991 Apr; 48(4): 303–7PubMedCrossRefGoogle Scholar
  191. 191.
    Nelson JC, Mazure CM, Jatlow PI, et al. Combining nor-epinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004 Feb; 55(3): 296–300PubMedCrossRefGoogle Scholar
  192. 192.
    Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999 Jan; 60(1): 45–9PubMedCrossRefGoogle Scholar
  193. 193.
    Zajecka JM, Jeffries H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry 1995 Aug; 56(8): 338–43PubMedGoogle Scholar
  194. 194.
    Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002 Jan; 51(2): 183–8PubMedCrossRefGoogle Scholar
  195. 195.
    Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin re-uptake inhibitors in major depression: a survey of current “next-step” practices. J Clin Psychiatry 2000 Jun; 61(6): 403–8PubMedCrossRefGoogle Scholar
  196. 196.
    Lam RW, Hossie H, Solomons K, et al. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry 2004 Mar; 65(3): 337–40PubMedCrossRefGoogle Scholar
  197. 197.
    Ramasubbu R. Treatment of resistant depression by adding noradrenergic agents to lithium augmentation of SSRIs. Ann Pharmacother 2002 Apr; 36(4): 634–40PubMedCrossRefGoogle Scholar
  198. 198.
    Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002 Mar; 63(3): 181–6PubMedCrossRefGoogle Scholar
  199. 199.
    DeBattista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psy-chopharmacol 2003 Feb; 23(1): 27–30CrossRefGoogle Scholar
  200. 200.
    Gitlin MJ, Suri R, Altshuler L, et al. Bupropion-sustained release as a treatment for SSRI-induced sexual side effects. J Sex Marital Ther 2002 Mar; 28(2): 131–8PubMedCrossRefGoogle Scholar
  201. 201.
    Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004 Feb; 25(1): 119–42PubMedCrossRefGoogle Scholar
  202. 202.
    Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006 Mar; 354(12): 1243–52PubMedCrossRefGoogle Scholar
  203. 203.
    Clayton AH, Warnock JK, Kornstein SG, et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004 Jan; 65(1): 62–7PubMedCrossRefGoogle Scholar
  204. 204.
    Zisook S, Rush AJ, Haight BR, et al. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006 Feb; 59(3): 203–10PubMedCrossRefGoogle Scholar
  205. 205.
    Demyttenaere K, Jaspers L. Review: Bupropion and SSRI-induced side effects. J Psychopharmacol 2008 Sep; 22(7): 792–804PubMedCrossRefGoogle Scholar
  206. 206.
    Dording CM, Mischoulon D, Petersen TJ, et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry 2002 Sep; 14(3): 143–7PubMedGoogle Scholar
  207. 207.
    Papakostas GI, Worthington III JJ, Iosifescu DV, et al. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 2006; 23(3): 178–81PubMedCrossRefGoogle Scholar
  208. 208.
    Fatemi SH, Emamian ES, Kist DA. Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. Ann Pharmacother 1999 Jun; 33(6): 701–3PubMedCrossRefGoogle Scholar
  209. 209.
    Hannan N, Hamzah Z, Akinpeloye HO, et al. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness. J Psychopharmacol 2007 Mar; 21(2): 161–4PubMedCrossRefGoogle Scholar
  210. 210.
    de Montigny C, Grunberg F, Mayer A, et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981 Mar; 138: 252–6PubMedCrossRefGoogle Scholar
  211. 211.
    Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression. Arch Gen Psychiatry 1983 Dec; 40(12): 1335–42PubMedCrossRefGoogle Scholar
  212. 212.
    Cournoyer G, de Montigny C, Ouellette J. Lithium addition in tricyclic-resistant unipolar depression: a placebo-controlled study [abstract]. 14th International College of Neuropsychopharmacology Congress; 1984 Jun 19–23; FlorenceGoogle Scholar
  213. 213.
    Kantor D, McNevin S, Leichner P, et al. The benefit of lithium carbonate adjunct in refractory depression: fact or fiction? Can J Psychiatry 1986 Jun; 31(5): 416–8PubMedGoogle Scholar
  214. 214.
    Zusky PM, Biederman J, Rosenbaum JF, et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol 1988 Apr; 8(2): 120–4PubMedCrossRefGoogle Scholar
  215. 215.
    Schopf J, Baumann P, Lemarchand T, et al. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: results of a placebo-controlled double-blind study. Pharmacopsychiatry 1989 Sep; 22(5): 183–7PubMedCrossRefGoogle Scholar
  216. 216.
    Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993 May; 50(5): 387–93PubMedCrossRefGoogle Scholar
  217. 217.
    Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993 May; 162: 634–40PubMedCrossRefGoogle Scholar
  218. 218.
    Katona CL, bou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995 Jan; 166(1): 80–6PubMedCrossRefGoogle Scholar
  219. 219.
    Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996 Aug; 16(4): 307–14PubMedCrossRefGoogle Scholar
  220. 220.
    Browne M, Lapierre YD, Hrdina PD, et al. Lithium as an adjunct in the treatment of major depression. Int Clin Psychopharmacol 1990 Apr; 5(2): 103–10PubMedCrossRefGoogle Scholar
  221. 221.
    Nierenberg AA, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 2003 Feb; 23(1): 92–5PubMedCrossRefGoogle Scholar
  222. 222.
    Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2001 Jul; 34(4): 119–27PubMedCrossRefGoogle Scholar
  223. 223.
    Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999 Oct; 19(5): 427–34PubMedCrossRefGoogle Scholar
  224. 224.
    Austin MP, Souza FG, Goodwin GM. Lithium augmentation in antidepressant-resistant patients. A quantitative analysis. Br J Psychiatry 1991 Oct; 159: 510–4Google Scholar
  225. 225.
    Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007 Jun; 68(6): 935–40PubMedCrossRefGoogle Scholar
  226. 226.
    Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006 Sep; 163(9): 1519–30PubMedCrossRefGoogle Scholar
  227. 227.
    Guzzetta F, Tondo L, Centorrino F, et al. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007 Mar; 68(3): 380–3PubMedCrossRefGoogle Scholar
  228. 228.
    Souza FG, Goodwin GM. Lithium treatment and prophylaxis unipolar depression: a meta-analysis. Br J Psychiatry 1991 May; 158: 666–75PubMedCrossRefGoogle Scholar
  229. 229.
    Hoencamp E, Haffmans J, Dijken WA, et al. Lithium augmentation of venlafaxine: an open-label trial. J Clin Psychopharmacol 2000 Oct; 20(5): 538–43PubMedCrossRefGoogle Scholar
  230. 230.
    Ontiveros A, Fontaine R, Elie R. Refractory depression: the addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand 1991 Mar; 83(3): 188–92PubMedCrossRefGoogle Scholar
  231. 231.
    Dallal A, Fontaine R, Ontiveros A, et al. Lithium carbonate augmentation of desipramine in refractory depression. Can J Psychiatry 1990 Oct; 35(7): 608–11PubMedGoogle Scholar
  232. 232.
    Schopf J, Lemarchand T. Lithium addition in endogenous depressions resistant to tricyclic antidepressants or related drugs: relation to the status of the pituitary-thyroid axis. Pharmacopsychiatry 1994 Sep; 27(5): 198–201PubMedCrossRefGoogle Scholar
  233. 233.
    Rybakowski JK, Suwalska A, Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsycho-biology 1999 Sep; 40(3): 134–9CrossRefGoogle Scholar
  234. 234.
    Manji HK, Potter WZ, Lenox RH. Signal transduction pathways. Molecular targets for lithium’s actions. Arch Gen Psychiatry 1995 Jul; 52(7): 531–43Google Scholar
  235. 235.
    Schopf J. Treatment of depressions resistant to tricyclic antidepressants, related drugs or MAO-inhibitors by lithium addition: review of the literature. Pharmacopsychiatry 1989 Sep; 22(5): 174–82PubMedCrossRefGoogle Scholar
  236. 236.
    DeBattista C. Augmentation and combination strategies for depression. J Psychopharmacol 2006 May; 20(3 Suppl.): 11–8PubMedCrossRefGoogle Scholar
  237. 237.
    Fahy S, Lawlor BA. Discontinuation of lithium augmentation in an elderly cohort. Int J Geriatr Psychiatry 2001 Oct; 16(10): 1004–9PubMedCrossRefGoogle Scholar
  238. 238.
    Ross J. Discontinuation of lithium augmentation in geriatric patients with unipolar depression: a systematic review. Can J Psychiatry 2008 Feb; 53(2): 117–20PubMedGoogle Scholar
  239. 239.
    Hardy BG, Shulman KI, Zucchero C. Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression. J Clin Psychopharmacol 1997 Feb; 17(1): 22–6PubMedCrossRefGoogle Scholar
  240. 240.
    Cavanagh J, Smyth R, Goodwin GM. Relapse into mania or depression following lithium discontinuation: a 7-year follow-up. Acta Psychiatr Scand 2004 Feb; 109(2): 91–5PubMedCrossRefGoogle Scholar
  241. 241.
    Prange Jr AJ, Wilson IC, Rabon AM, et al. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969 Oct; 126(4): 457–69PubMedGoogle Scholar
  242. 242.
    Abraham G, Milev R, Stuart LJ. T3 augmentation of SSRI resistant depression. J Affect Disord 2006 Apr; 91(2–3): 211–5PubMedCrossRefGoogle Scholar
  243. 243.
    Gitlin MJ, Weiner H, Fairbanks L, et al. Failure of T3 to potentiate tricyclic antidepressant response. J Affect Disord 1987 Nov; 13(3): 267–72PubMedCrossRefGoogle Scholar
  244. 244.
    Goodwin FK, Prange Jr AJ, Post RM, et al. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982 Jan; 139(1): 34–8PubMedGoogle Scholar
  245. 245.
    Thase ME, Kupfer DJ, Frank E, et al. Treatment of imipramine-resistant recurrent depression: II. An open clinical trial of lithium augmentation. J Clin Psychiatry 1989 Nov; 50(11): 413–7Google Scholar
  246. 246.
    Lojko D, Rybakowski JK. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. J Affect Disord 2007 Nov; 103(1–3): 253–6PubMedCrossRefGoogle Scholar
  247. 247.
    Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodo-thyronine supplementation in patients with major depressive disorder treated with specific serotonin re-uptake inhibitors. Int J Neuropsychopharmacol 2008; 11 5: 685–99Google Scholar
  248. 248.
    Bauer M, Hellweg R, Graf KJ, et al. Treatment of refractory depression with high-dose thyroxine. Neuro-psychopharmacology 1998 Jun; 18(6): 444–55CrossRefGoogle Scholar
  249. 249.
    Hickie I, Bennett B, Mitchell P, et al. Clinical and sub-clinical hypothyroidism in patients with chronic and treatment-resistant depression. Aust N Z J Psychiatry 1996 Apr; 30(2): 246–52PubMedCrossRefGoogle Scholar
  250. 250.
    Vandoolaeghe E, Maes M, Vandevyvere J, et al. Hypothalamic-pituitary-thyroid-axis function in treatment resistant depression. J Affect Disord 1997 Apr; 43(2): 143–50PubMedCrossRefGoogle Scholar
  251. 251.
    Iosifescu DV, Bolo NR, Nierenberg AA, et al. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry 2008 Jun 15; 63(12): 1127–34PubMedCrossRefGoogle Scholar
  252. 252.
    Rogoz Z, Dziedzicka-Wasylewska M, Daniel WA, et al. Effects of joint administration of imipramine and aman-tadine in patients with drug-resistant unipolar depression. Pol J Pharmacol 2004 Nov; 56(6): 735–42PubMedGoogle Scholar
  253. 253.
    Stryjer R, Strous RD, Shaked G, et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 2003 Mar; 18(2): 93–6PubMedCrossRefGoogle Scholar
  254. 254.
    Lattanzi L, Dell’Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002 Oct; 4(5): 307–14PubMedCrossRefGoogle Scholar
  255. 255.
    Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 2004; 20(3): 131–8PubMedCrossRefGoogle Scholar
  256. 256.
    Perugi G, Toni C, Ruffolo G, et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001 Jul; 34(4): 137–41PubMedCrossRefGoogle Scholar
  257. 257.
    Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005 May; 50(6): 357–60PubMedGoogle Scholar
  258. 258.
    Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991 May; 52(5): 217–20PubMedGoogle Scholar
  259. 259.
    Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993 Jul; 54(7): 269–71PubMedGoogle Scholar
  260. 260.
    Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998 Dec; 18(6): 465–9PubMedCrossRefGoogle Scholar
  261. 261.
    Bakish D. Fluoxetine potentiation by buspirone: three case histories. Can J Psychiatry 1991 Dec; 36(10): 749–50PubMedGoogle Scholar
  262. 262.
    Fischer P, Tauscher J, Kufferle B, et al. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. Int Clin Psychopharmacol 1998 Mar; 13(2): 83–6PubMedCrossRefGoogle Scholar
  263. 263.
    Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. S Afr Med J 1997 Apr; 87(4 Suppl.): 534–7, 540PubMedGoogle Scholar
  264. 264.
    Onder E, Tural U. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. J Affect Disord 2003 Sep; 76(1–3): 223–7PubMedCrossRefGoogle Scholar
  265. 265.
    Appelberg BG, Syvalahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001 Jun; 62(6): 448–52PubMedCrossRefGoogle Scholar
  266. 266.
    Landen M, Bjorling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998 Dec; 59(12): 664–8PubMedCrossRefGoogle Scholar
  267. 267.
    Fava M. The combination of buspirone and bupropion in the treatment of depression. Psychother Psychosom 2007; 76(5): 311–2PubMedCrossRefGoogle Scholar
  268. 268.
    Schweitzer I, Tuckwell V. Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression. Drug Saf 1998 Dec; 19(6): 455–64PubMedCrossRefGoogle Scholar
  269. 269.
    Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 2005; 66 Suppl. 8: 13–21Google Scholar
  270. 270.
    Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007 Jan; 13(1): 13–24PubMedCrossRefGoogle Scholar
  271. 271.
    Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002 Dec; 63(12): 1156–63PubMedCrossRefGoogle Scholar
  272. 272.
    Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001 Jan; 158(1): 131–4PubMedCrossRefGoogle Scholar
  273. 273.
    Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007 Feb; 68(2): 224–36PubMedCrossRefGoogle Scholar
  274. 274.
    Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23(6): 364–72PubMedCrossRefGoogle Scholar
  275. 275.
    Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005 Oct; 66(10): 1289–97PubMedCrossRefGoogle Scholar
  276. 276.
    Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009; 70(3): 387–96PubMedCrossRefGoogle Scholar
  277. 277.
    Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003 Nov; 64(11): 1349–56PubMedCrossRefGoogle Scholar
  278. 278.
    Michelson D, Kociban K, Tamura R, et al. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. J Psychiatr Res 2002 May; 36(3): 147–52PubMedCrossRefGoogle Scholar
  279. 279.
    Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003 Nov; 60(11): 1079–88PubMedCrossRefGoogle Scholar
  280. 280.
    Rothschild AJ, Williamson DJ, Tohen MF, et al. A doubleblind, randomized study of olanzapine and olanzapine/ fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004 Aug; 24(4): 365–73PubMedCrossRefGoogle Scholar
  281. 281.
    Zyprexa® (olanzapine) [package insert]. Eli Lilly and Company, 2007 Indianapolis, IndianaGoogle Scholar
  282. 282.
    Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004 Jul; 65(7): 975–81PubMedCrossRefGoogle Scholar
  283. 283.
    Sagud M, Mihaljevic-Peles A, Muck-Seler D, et al. Quetiapine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology (Berl) 2006 Sep; 187(4): 511–4CrossRefGoogle Scholar
  284. 284.
    Devarajan S, Ali J, Dursun SM. Quetiapine plus SSRI in treatment-resistant depression: possible mechanisms. Psychopharmacology (Berl) 2006 Apr; 185(3): 402–3CrossRefGoogle Scholar
  285. 285.
    Anderson IM, Sarsfield A, Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study. J Affect Disord 2009 Sep; 117(1–2): 116–9PubMedCrossRefGoogle Scholar
  286. 286.
    Dorée JP, Des Rosiers J, Lew V, et al. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 2007 Feb; 23(2): 333–41PubMedCrossRefGoogle Scholar
  287. 287.
    Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psy-chopharmacol 2007 Jan; 22(1): 1–9CrossRefGoogle Scholar
  288. 288.
    Pathak S, Johns ES, Kowatch RA. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J Child Adolesc Psychopharmacol 2005 Aug; 15(4): 696–702PubMedCrossRefGoogle Scholar
  289. 289.
    Ostroff RB, Nelson JC. Risperidone augmentation of selective erotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999 Apr; 60(4): 256–9PubMedCrossRefGoogle Scholar
  290. 290.
    Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008 Jan; 16(1): 21–30PubMedCrossRefGoogle Scholar
  291. 291.
    Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsycho-pharmacology 2006 Nov; 31(11): 2505–13CrossRefGoogle Scholar
  292. 292.
    Gharabawi GM, Canuso CM, Pandina G, et al. A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder. Int J Neuropsychopharmacol 2006; 9Suppl. 1: S236Google Scholar
  293. 293.
    Keitner GI, Garlow S, Ryan CE, et al. Risperidone augmentation for patients with difficult-to-treat major depression [poster]. American Psychiatric Association Annual Meeting; 2006 May 20–25; Toronto (ON)Google Scholar
  294. 294.
    Svestka J, Synek O, Tomanova J, et al. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett 2007 Dec; 28(6): 881–8PubMedGoogle Scholar
  295. 295.
    Schmidt AW, Lebel LA, Howard Jr HR, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001 Aug; 425(3): 197–201PubMedCrossRefGoogle Scholar
  296. 296.
    Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004 Feb; 65(2): 217–21PubMedCrossRefGoogle Scholar
  297. 297.
    Dunner DL, Amsterdam JD, Shelton RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007 Jul; 68(7): 1071–7PubMedCrossRefGoogle Scholar
  298. 298.
    Schule C, Baghai TC, Eser D, et al. Mirtazapine mono-therapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World J Biol Psychiatry 2007; 8(2): 112–22PubMedCrossRefGoogle Scholar
  299. 299.
    Patkar AA, Peindl K, Mago R, et al. An open-label, rater-blinded, ugmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 2006; 8(2): 82–7PubMedCrossRefGoogle Scholar
  300. 300.
    Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005 Oct; 66(10): 1326–30PubMedCrossRefGoogle Scholar
  301. 301.
    Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005 Oct; 66(10): 1216–20PubMedCrossRefGoogle Scholar
  302. 302.
    Hellerstein DJ, Batchelder S, Hyler S, et al. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Prog Neuropsychopharmacol Biol Psychiatry 2008 Apr; 32(3): 744–50PubMedCrossRefGoogle Scholar
  303. 303.
    Worthington III JJ, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005 Jan; 20(1): 9–11PubMedCrossRefGoogle Scholar
  304. 304.
    Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004 Oct; 16(4): 189–94PubMedCrossRefGoogle Scholar
  305. 305.
    Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007 Jun; 68(6): 843–53PubMedCrossRefGoogle Scholar
  306. 306.
    Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009 Apr; 14(4): 197–206PubMedGoogle Scholar
  307. 307.
    Abilify (aripipraxole) [package insert]. Otsuka Pharmaceutical Co., 2008 Tokyo, JapanGoogle Scholar
  308. 308.
    Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994 Mar; 51(3): 248–51PubMedCrossRefGoogle Scholar
  309. 309.
    Moreno FA, Gelenberg AJ, Bachar K, et al. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry 1997 Oct; 58(10): 437–9PubMedCrossRefGoogle Scholar
  310. 310.
    Perez V, Soler J, Puigdemont D, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors: Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry 1999 Apr; 56(4): 375–9PubMedCrossRefGoogle Scholar
  311. 311.
    Perry EB, Berman RM, Sanacora G, et al. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J Clin Psychiatry 2004 Feb; 65(2): 238–43PubMedCrossRefGoogle Scholar
  312. 312.
    Bakish D, Hooper CL, Thornton MD, et al. Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. Int Clin Psychopharmacol 1997 Mar; 12(2): 91–7PubMedCrossRefGoogle Scholar
  313. 313.
    Blier P, Bergeron R, De Montigny C. Selective activation of postsynaptic 5-HT1A receptors induces rapid anti-depressant response. Neuropsychopharmacology 1997 May; 16(5): 333–8PubMedCrossRefGoogle Scholar
  314. 314.
    Zanardi R, Artigas F, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 1997 Dec; 17(6): 446–50PubMedCrossRefGoogle Scholar
  315. 315.
    Perez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997 May; 349(9065): 1594–7PubMedCrossRefGoogle Scholar
  316. 316.
    Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997 Mar; 12(2): 81–9PubMedCrossRefGoogle Scholar
  317. 317.
    Berman RM, Darnell AM, Miller HL, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997 Jan; 154(1): 37–43PubMedGoogle Scholar
  318. 318.
    Blier P, Bergeron R. Sequential administration of augmentation trategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol 1996 Mar; 11(1): 37–44PubMedCrossRefGoogle Scholar
  319. 319.
    Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996 Dec; 41(3): 201–10PubMedCrossRefGoogle Scholar
  320. 320.
    Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995 Jun; 15(3): 217–22PubMedCrossRefGoogle Scholar
  321. 321.
    Dursun SM, Devarajan S, Kutcher S. The ‘dalhousie serotonin cocktail’ for treatment-resistant major depressive disorder. J Psychopharmacol 2001 Jun; 15(2): 136–8PubMedCrossRefGoogle Scholar
  322. 322.
    Rasanen P, Hakko H, Tiihonen J, et al. Balter Award: 1998. Pindolol and major affective disorders: a three-year follow-up study of 30,485 patients. J Clin Psychopharmacol 1999 Aug; 19(4): 297–302Google Scholar
  323. 323.
    Artigas F, Romero L, De Montigny C, et al. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996 Sep; 19(9): 378–83PubMedCrossRefGoogle Scholar
  324. 324.
    Celada P, Puig M, Margos-Bosch M, et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004 Jul; 29(4): 252–65PubMedGoogle Scholar
  325. 325.
    Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 1998; 59 Suppl. 5: 16–23Google Scholar
  326. 326.
    Kraus RP. Rapid cycling triggered by pindolol augmentation of paroxetine, but not with desipramine. Depression 1996; 4(2): 92–4PubMedCrossRefGoogle Scholar
  327. 327.
    Nemets B, Mishory A, Levine J, et al. Inositol addition does not improve depression in SSRI treatment failures. J Neural Transm 1999; 106(7–8): 795–8PubMedCrossRefGoogle Scholar
  328. 328.
    Levine J, Mishori A, Susnosky M, et al. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry 1999 Feb; 45(3): 270–3PubMedCrossRefGoogle Scholar
  329. 329.
    Fawcett J, Kravitz HM, Zajecka JM, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991 Apr; 11(2): 127–32PubMedCrossRefGoogle Scholar
  330. 330.
    Murphy BE, Dhar V, Ghadirian AM, et al. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol 1991 Apr; 11(2): 121–6PubMedGoogle Scholar
  331. 331.
    Murphy BE, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993 Nov; 18(5): 209–13PubMedGoogle Scholar
  332. 332.
    Ghadirian AM, Engelsmann F, Dhar V, et al The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 1995 Mar; 37(6): 369–75PubMedCrossRefGoogle Scholar
  333. 333.
    Dinan TG, Lavelle E, Cooney J, et al. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand 1997 Jan; 95(1): 58–61PubMedCrossRefGoogle Scholar
  334. 334.
    Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997 Feb; 41(3): 311–8PubMedCrossRefGoogle Scholar
  335. 335.
    Wolkowitz OM, Reus VI. Treatment of depression with antiglucocorticoid drugs. Psychosom Med 1999 Sep; 61(5): 698–711PubMedGoogle Scholar
  336. 336.
    Bouwer C, Claassen J, Dinan TG, et al. Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolaemia: a case series. Depress Anxiety 2000; 12(1): 44–50PubMedCrossRefGoogle Scholar
  337. 337.
    Rogoz Z, Skuza G, Wojcikowski J, et al. Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression. Pol J Pharmacol 2004 Nov; 56(6): 849–55PubMedGoogle Scholar
  338. 338.
    Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol 2005 Mar; 18(1): 20–4PubMedCrossRefGoogle Scholar
  339. 339.
    Seidman SN, Miyazaki M, Roose SP. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial. J Clin Psychopharmacol 2005 Dec; 25(6): 584–8PubMedCrossRefGoogle Scholar
  340. 340.
    Dalton EJ, Rotondi D, Levitan RD, et al. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci 2000 Jan; 25(1): 48–52PubMedGoogle Scholar
  341. 341.
    Ruhwinkel B, Tolle R. Modified insulin treatment of therapy refractory depression. Psychiatr Prax 1995 Mar; 22(2): 64–7PubMedGoogle Scholar
  342. 342.
    Kasper S, Anghelescu IG, Szegedi A, et al. Superior efficacy of St John’s wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial (ISRCTN77277298) [letter]. BMC Med 2006; 4: 14PubMedCrossRefGoogle Scholar
  343. 343.
    Fava M, Alpert J, Nierenberg AA, et al. A Double-blind, randomized trial of St John’s wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005 Oct; 25(5): 441–7PubMedCrossRefGoogle Scholar
  344. 344.
    Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Psychiatr Clin North Am 2007 Mar; 30(1): 51–68PubMedCrossRefGoogle Scholar
  345. 345.
    Hibbeln JR. Fish consumption and major depression [letter]. Lancet 1998 Apr; 351(9110): 1213PubMedCrossRefGoogle Scholar
  346. 346.
    Appleton KM, Peters TJ, Hayward RC, et al. Depressed mood and n-3 polyunsaturated fatty acid intake from fish: non-linear or confounded association? Soc Psychiatry Psychiatr Epidemiol 2007 Feb; 42(2): 100–4PubMedCrossRefGoogle Scholar
  347. 347.
    Appleton KM, Woodside JV, Yarnell JW, et al. Depressed mood and dietary fish intake: direct relationship or indirect relationship as a result of diet and lifestyle? J Affect Disord 2007 Dec; 104(1–3): 217–23PubMedCrossRefGoogle Scholar
  348. 348.
    Puri BK, Counsell SJ, Richardson AJ, et al. Eicosa-pentaenoic acid in treatment-resistant depression. Arch Gen Psychiatry 2002 Jan; 59(1): 91–2PubMedCrossRefGoogle Scholar
  349. 349.
    Nemets B, Stahl Z, Belmaker RH. Addition of omega-3fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002 Mar; 159(3): 477–9PubMedCrossRefGoogle Scholar
  350. 350.
    Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002 Oct; 59(10): 913–9PubMedCrossRefGoogle Scholar
  351. 351.
    Rosenbaum JF, Fava M, Falk WE, et al. The anti-depressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990 May; 81(5): 432–6PubMedCrossRefGoogle Scholar
  352. 352.
    Alpert JE, Papakostas G, Mischoulon D, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 2004 Dec; 24(6): 661–4PubMedCrossRefGoogle Scholar
  353. 353.
    Papakostas GI, Petersen T, Mischoulon D, et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder: part I. Predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry 2004 Aug; 65(8): 1090–5Google Scholar
  354. 354.
    Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000 Nov; 60(2): 121–30PubMedCrossRefGoogle Scholar
  355. 355.
    Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study. Depress Anxiety 2006; 23(8): 485–8PubMedCrossRefGoogle Scholar
  356. 356.
    Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol 2007 May; 22(3): 179–82PubMedCrossRefGoogle Scholar
  357. 357.
    Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003 Apr; 64(4): 403–7PubMedCrossRefGoogle Scholar
  358. 358.
    Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry 2008; 10(3): 187–90PubMedCrossRefGoogle Scholar
  359. 359.
    Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr 2006 Feb; 11(2): 93–102PubMedGoogle Scholar
  360. 360.
    DeBattista C, Lembke A, Solvason HB, et al. A prospective rial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol 2004 Feb; 24(1): 87–90PubMedCrossRefGoogle Scholar
  361. 361.
    Rasmussen NA, Schroder P, Olsen LR, et al. Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92). Nord J Psychiatry 2005; 59(3): 173–8PubMedCrossRefGoogle Scholar
  362. 362.
    Price CS, Taylor FB. A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. Depress Anxiety 2005; 21(4): 149–53PubMedCrossRefGoogle Scholar
  363. 363.
    Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000 May; 61(5): 378–81PubMedCrossRefGoogle Scholar
  364. 364.
    Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005 Jan; 66(1): 85–93PubMedCrossRefGoogle Scholar
  365. 365.
    Kugaya A, Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 2005 Oct; 10(10): 808–19PubMedGoogle Scholar
  366. 366.
    Zarate Jr CA, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004 Jan; 161(1): 171–4PubMedCrossRefGoogle Scholar
  367. 367.
    Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007 Mar; 61(6): 822–5PubMedCrossRefGoogle Scholar
  368. 368.
    Sanacora G, Kendell SF, Fenton L, et al. Riluzole augmentation for treatment-resistant depression [letter]. Am J Psychiatry 2004 Nov; 161(11): 2132PubMedCrossRefGoogle Scholar
  369. 369.
    Nickel C, Lahmann C, Tritt K, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J Affect Disord 2005 Aug; 87(2–3): 243–52PubMedCrossRefGoogle Scholar
  370. 370.
    Klufas A, Thompson D. Topiramate-induced depression [letter]. Am J Psychiatry 2001 Oct; 158(10): 1736PubMedCrossRefGoogle Scholar
  371. 371.
    Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry 2003 Apr; 53(8): 640–8PubMedCrossRefGoogle Scholar
  372. 372.
    Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry 2005; 66 Suppl. 8: 5–12Google Scholar
  373. 373.
    Pridmore S, Turnier-Shea Y. Medication options in the treatment of treatment-resistant depression. Aust N Z J Psychiatry 2004 Apr; 38(4): 219–25PubMedCrossRefGoogle Scholar
  374. 374.
    Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 2001; 15(10): 765–76PubMedCrossRefGoogle Scholar
  375. 375.
    Carvalho AF, Cavalcante JL, Castelo MS, et al. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther 2007 Oct; 32(5): 415–28PubMedCrossRefGoogle Scholar
  376. 376.
    Philip NS, Carpenter LL, Tyrka AR, et al. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J Psychiatr Pract 2008 Jan; 14(1): 34–44PubMedCrossRefGoogle Scholar
  377. 377.
    Alao AO, Malhotra K, Pies R, et al. Pharmacological strategies in treatment-resistant depression. West Afr J Med 2003Sep;22(3):211–8PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Richard C. Shelton
    • 1
  • Olawale Osuntokun
    • 2
  • Alexandra N. Heinloth
    • 3
  • Sara A. Corya
    • 2
  1. 1.Department of PsychiatryVanderbilt University School of Medicine NashvilleTennesseeUSA
  2. 2.Eli Lilly and Company, Lilly Corporate CenterIndianapolisUSA
  3. 3.i3Statprobe, IngenixAnn ArborUSA

Personalised recommendations